Christine M. Peat, PhD Postdoctoral Fellow, Eating Disorders Program, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC Kimberly A. Brownley, PhD Assistant Professor, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC Nancy D. Berkman, PhD Senior Health Policy Research Analyst, Health Care Quality and Outcomes Program, RTI International, Research Triangle Park, NC Cynthia M. Bulik, PhD, FAED Distinguished Professor of Eating Disorders, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC
In light of these findings, we recommend augmenting psychotherapeutic care with pharmacotherapy and medical management to address all relevant psychological and medical domains. Future investigations should address the benefits of coordinated psychological and medical care and evaluate how to maintain treatment gains.
Clinical Point
All BED patients should receive medical management to address possible complications such as hypertension or type 2 diabetes
Brownley KA, Berkman ND, Sedway JA, et al. Binge eating disorder treatment: a systematic review of randomized controlled trials. Int J Eat Disord. 2007;40(4):337-348.
Drug Brand Names
Atomoxetine • Strattera
Escitalopram • Lexapro
Fluoxetine • Prozac
Lamotrigine • Lamictal
Memantine • Namenda
Orlistat • Alli, Xenical
Sertraline • Zoloft
Sibutramine • Meridia
Topiramate • Topamax, Topiragen
Zonisamide • Zonegram
Disclosures
Dr. Peat receives a post-doctoral trainee grant from the National Institutes of Health.
Drs. Brownley, Berkman, and Bulik report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
